"The expansion of IRIS staging to SDMA-based guidelines is a further proof point for this novel biomarker. IRIS has recognized how SDMA reflects kidney function. These updated SDMA-based staging guidelines will support clinicians in managing their CKD patients by staging and treating this condition appropriately," said Jay Mazelsky, interim President and Chief Executive Officer of IDEXX Laboratories. "We're thrilled to partner with IRIS on this important development that we know will help more veterinarians improve the standard of care by incorporating SDMA into their workflow."